The August 12 issue of Dave Harmon's MarketScopes Ophthalmic Market Perspectives has a listing of dry eye products in FDA approval process as follows:
Alcon/Lantibio's VISMED (HA drop)- turned down by FDA in June, recommended additional Phase III trial. VisMed is on the market in Europe.
Alcon's VEXOL (non steroidal anti-inflammatory) - completed Phase II trial
ArGentis' ARG101/102 (testosterone topical cream) - completed Phase II trial
Inspire's PROLACRIA (secretagogue) - in Phase III (again)
Lantibio's MOLI1901 (secretagogue) - in Phase III
Sirion's ST609 (cyclosporine 0.1%) - in Phase III
Novagali's CYCLOKAT (cyclosporine with cationic emulsion) - completed Phase II trial
Novagali's CATIONORM (lubricating emulsion) - in Phase III
Ista's XIBROM (low dose steroid) - Phase IIB trial completed
Ista's Ecabet Sodium (secretagogue) - Phase II trial completed
EyeGate's EGP-437 (iontophoresis with dexamethasone) - Phase II trial completed
Otsuka/Acucela's Rebamipide (secretagogue) - in Phase III
1 comment:
Thanks for this blog, Rebecca! I have high hopes in new treatments, expecting somewhere in the future something will come up to effectively treat our conditions. Your posts are really helpful to keep my hopes up! Keep going! :)
Post a Comment